The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy

Disrupted topology of the functional white matter connectome in thyroid-associated ophthalmopathy

BACKGROUND

This study aims to investigate the changes in the topological organization of WM functional connectivity in individuals with TAO, providing a novel and insightful perspective on the functional disruptions that characterize this condition.

METHODS

This study utilized resting-state functional Magnetic Resonance Imaging (rs-fMRI) to capture blood-oxygen-level-dependent (BOLD) signals and T1-weighted images from patients with TAO and healthy control subjects. Group-level masks for white matter were created to extract WM-related BOLD signals, facilitating the construction of a functional white matter network. Graph theory analysis was subsequently conducted to evaluate global metrics, nodal metrics, and modularity, alongside network-based analysis. Finally, support vector machines (SVM) were employed for classification.

RESULTS

A functional white matter network comprising 128 nodes and their respective connections was identified. The graph theory analysis revealed significant differences primarily in the sigma characteristic of the global small-world metrics, with a notable decrease in betweenness centrality observed in the splenium of the corpus callosum. Modularity analysis indicated significant intra-module variations in modules 03 and 05, while strong inter-module connections were observed between modules 01 and 03, as well as between modules 02 and 04. Furthermore, network-based statistics (NBS) highlighted 13 networks that exhibited significant alterations in the TAO group compared to healthy controls, underscoring the potential impact of TAO on the organization of white matter networks.

CONCLUSION

In our study, we found that patients with TAO exhibited abnormalities in the white matter functional network regarding small-world metrics and modularity, which are related to visual and cognitive functions.

Graves' Disease: Is It Time for Targeted Therapy? A Narrative Review

Current therapies for Graves' disease (GD) primarily aim to manage hyperthyroidism through synthetic antithyroid drugs, radioiodine, or surgery. However, these approaches are often limited by their incomplete efficacy and the risk of inducing hypothyroidism. The latest advances in understanding the autoimmune mechanisms driving GD have paved the way for novel therapies targeting the thyrotropin receptor (TSH-R) or immune pathways. Overall, key targets include cluster of differentiation 20 (CD20), cluster of differentiation 40 (CD40), protein tyrosine phosphatase non-receptor type 22 (PTPN22), cytotoxic T lymphocyte antigen-4 (CTLA-4), B cell-activating factor (BAFF), and the Fc receptor-like protein 3 (FcRL3). Recent preclinical studies and clinical trials testing targeted therapies have shown promising results in terms of efficacy and safety. Here, we present a narrative review of the literature on emerging therapeutic approaches for GD that are currently under investigation.

Targeted immunotherapies for Graves' thyroidal & orbital diseases

Background

Graves' hyperthyroidism and its associated Graves' orbitopathy are common autoimmune disorders associated with significant adverse health impact. Current standard treatments have limitations regarding efficacy and safety, and most do not specifically target the pathogenic mechanisms. We aim to review the latest development of targeted immunotherapies in these two closely related disorders.

Summary

Targeted immunotherapies of Graves' hyperthyroidism have recently demonstrated clinical efficacy in early phase clinical studies. They include rituximab, an anti-CD20 monoclonal antibody which causes rapid B cell depletion; ATX-GD-59, an antigen specific immunotherapy which restores immune tolerance to thyrotropin receptor; iscalimab, an anti-CD40 monoclonal antibody which blocks the CD40-CD154 co-stimulatory pathway in B-T cell interaction; and K1-70, a thyrotropin receptor blocking monoclonal antibody. Furthermore, there have been major therapeutic advances in the management of Graves' orbitopathy. Mycophenolate has a dual mechanism of action both inhibiting the proliferation of activated B & T cells as well as the mammalian target of rapamycin growth intracellular pathway. Rituximab appears to be effective in active disease of recent onset without impending dysthyroid optic neuropathy. Both tocilizumab (anti-interleukin 6 receptor monoclonal antibody) and sirolimus (mammalian target of rapamycin inhibitor) showed promise in glucocorticoid resistant active disease. Teprotumumab, an anti-insulin-like growth factor-1 receptor monoclonal antibody, demonstrated remarkable all-round efficacy across a wide disease spectrum. Linsitinib, a dual small molecule inhibitor of insulin-like growth factor-1 receptor and insulin receptor, displayed significant proptosis reduction in its phase 2b/3 study. Finally, Batoclimab, an anti-neonatal fragment crystallizable receptor monoclonal antibody, which blocks recycling of pathogenic thyrotropin receptor antibody, showed promising signals for significant proptosis reduction, disease inactivation, overall response, and improvement of quality of life.

Conclusion

Therapeutic advances will continue to optimize our management of Graves' hyperthyroidism and its associated orbitopathy in an effective and safe manner.

Inflammatory profiling and immune cell infiltration in dysthyroid optic neuropathy: insights from bulk RNA sequencing

Background

Dysthyroid optic neuropathy (DON), the most severe complication of thyroid eye disease (TED), has unclear mechanisms and unsatisfactory treatment outcomes. This study aimed to identify key pathways and inflammation-related core genes driving DON progression, potentially informing new therapeutic strategies and improving disease management.

Methods

Retro-orbital tissues from DON, non-DON TED, and healthy controls (HCs) were analyzed using bulk RNA sequencing. Differentially expressed genes (DEGs) were identified and subjected to Gene Ontology (GO) enrichment analysis. Weighted gene co-expression network analysis (WGCNA) identified disease-relevant modules. Immune cell infiltration was assessed via single-sample Gene Set Enrichment Analysis (ssGSEA). ROC analysis and single-gene GSEA were used to evaluate the diagnostic potential and functional relevance of core genes. Inflammatory-Related Differential Genes (IRDGS) were identified and preliminarily validated using Quantitative Real-Time PCR.

Results

Differential gene expression analysis revealed 176 and 202 significantly upregulated genes in DON vs. non-DON and DON vs. HCs comparisons, respectively. Notably, inflammation-related genes, including CXCL14, CCL21, HP, and fibrosis-associated genes such as MGP, FN1, and COL11A1, were significantly upregulated in DON group. GO enrichment analyses identified immune-related processes like lymphocyte proliferation, cytokine activity, and extracellular matrix remodeling. WGCNA further identified key gene modules associated with inflammation and tissue remodeling in DON, and IRDCGs, such as CCL21, HP, and SLCO2A1, emerged as the most significant markers. Single-gene GSEA confirmed that these genes are involved in immune response, inflammation, and fibrosis-related processes. Immune cell infiltration analysis using ssGSEA revealed that DON patients exhibited significantly increased infiltration of activated B cells, CD4 T cells, mast cells, and Th1 cells, and correlation analysis showed that IRDGs were significantly associated with multiple immune cell types, particularly activated B cells and regulatory T cells. Finally, qPCR validation of the top 10 IRDEGs in retro-orbital tissues showed that HP, TPSAB1, and PLA2G2A were significantly upregulated in the DON.

Conclusions

This is the first study to identify the key molecular and immune drivers of DON through bulk transcriptomic analysis, emphasizing the central role of inflammation-related molecules and immune cell infiltration in its pathogenesis. The identified IRDGs and their associated pathways provide novel insights for innovative diagnostic and therapeutic strategies.

The etiologic and pathogenic spectrum of exposure keratopathy: Diagnostic and therapeutic implications

Exposure keratopathy (EK) is an underestimated ocular surface disorder that involves multiple underlying pathophysiologic mechanisms. It results from an exposed cornea due to different causes of eyelid insufficiency or blinking dysfunction, ocular globe protrusion, a negative orbital vector, and diverse contributing factors leading to impaired ocular surface homeostasis and the potential for vision loss. EK can be congenital, acquired, or induced, and various risk factors predispose patients to corneal exposure. These causes can be grouped into those related to proptosis and eyelid malformations, malfunctioning, or acquired deformity. If detected early, EK offers a range of effective treatment options. The superficial punctate keratitis and dryness of the cornea's lower third can be successfully treated at the initial stages; however, if left untreated, EK can progress to extensive epithelial erosion, persistent epithelial defects, stromal melting, vascularization, squamous metaplasia, and opportunistic infections, leading to significant visual loss. Different and varied treatment modalities, including medical and surgical, are available for patients with EK, depending on the disease stage, the underlying mechanism, and the cause. We examine the risk factors, causes, and range of pathologies associated with EK. Exploring the mechanisms that contribute to the development of the disorder's clinical manifestations provides valuable insights that can help clinicians detect and diagnose the disease promptly and plan appropriate targeted treatments.

Orbital Clinicopathological Differences in Thyroid Eye Disease: An Analysis of Cytokines With Histopathological and Clinical Correlation

Purpose

To explore the pathological differences in orbital adipose/connective tissue between active and inactive thyroid eye disease (TED) subjects and their correlations with clinical characteristics.

Methods

Orbital adipose/connective tissue samples from 42 TED subjects (20 active, 22 inactive) were collected during decompression surgery. We analyzed cytokine expression, inflammatory cell infiltration, inherent cell populations, and interstitial changes by Luminex and histopathology. Correlations were analyzed using Pearson and Spearman correlation analyses.

Results

Among the 108 cytokines detected, active TED exhibited elevated platelet endothelial cell adhesion molecule 1 (PECAM-1), interleukin-23 (IL-23), a proliferation-inducing ligand (APRIL), IL-6, C-C motif chemokine ligand 2 (CCL2), β-nerve growth factor (NGF), and lower CCL21 and CCL5. The extent of infiltration by helper T (Th) cells and monocytes was significantly greater in the active group than in the inactive group. Adipocyte density was significantly elevated in active TED, whereas fibrosis was more prominent in inactive TED. Fifteen cytokines were significantly associated with inflammatory cell infiltration, with IL-16 showing the strongest correlations with T cells. Ten cytokines showed significant positive correlations with fibrosis. Four cytokines (IL-6, PECAM-1, IL-23 and transforming growth factor β1), Th cell infiltration and adipocyte density were significantly positively correlated with clinical activity score (CAS). Sixteen cytokines, along with adipocyte density, were significantly positively correlated with disease severity of TED.

Conclusions

The orbital adipose/connective tissues of active and inactive TED subjects showed significant differences in terms of cytokines, inflammatory cells infiltration, inherent cells and interstitium. These pathological changes were correlated with clinical characteristics of TED.

LncRNA ENST00000581911 Regulates Extraocular Muscle Remodeling by Interacting With KHSRP in Thyroid Eye Disease

Purpose

Thyroid eye disease (TED) is a visually debilitating and cosmetically disfiguring orbital disorder, characterized by the remodeling of extraocular muscles (EOMs). This study aimed to investigate the role of long non-coding RNA (lncRNA) ENST00000581911 in the EOMs of TED.

Methods

LncRNA microarray analysis was performed on EOM tissues sampled from patients with TED and patients with concomitant esotropia. LncRNA ENST00000581911 was identified and subjected to bioinformatics analysis. High-throughput RNA sequencing, CCK-8 assay, CFSE staining, and ELISA were used to investigate the regulatory function of ENST00000581911 in vitro. Furthermore, RNA pull-down, liquid chromatography-tandem mass spectrometry (LC-MS/MS), and western blot (WB) analyses were applied to identify the RNA-binding protein (RBP) interacting with ENST00000581911.

Results

A total of 1261 lncRNAs were found to be differentially expressed in the EOMs of TED, with 648 upregulated and 613 downregulated lncRNAs. Among these, the upregulated lncRNA ENST00000581911 exhibited the highest expression level, as validated by quantitative real-time PCR (qRT-PCR). Functional analysis demonstrated that ENST00000581911 might be involved in inflammatory response, regulation of muscle contraction, and amino sugar and nucleotide sugar metabolism. RNA sequencing of ENST00000581911-overexpressing and control orbital fibroblasts (OFs) showed that ENST00000581911 might play a regulatory role in DNA replication, extracellular matrix, and cell cycle. Furthermore, KHSRP was identified as the RBP of ENST00000581911. Overexpression of ENST00000581911 promoted cell proliferation and hyaluronic acid secretion in OFs, whereas silencing KHSRP attenuated these effects.

Conclusions

This study provides novel insights into the role of lncRNA ENST00000581911 in the pathogenesis of EOM remodeling in TED. ENST00000581911 may serve as a potential therapeutic target of TED.

Perioperative Use of Systemic Steroids Within Otolaryngology-Head and Neck Surgery: Evidence-Based Guidance for Clinicians

OBJECTIVE

To review and synthesize the available evidence for use of perioperative systemic steroids for otolaryngologic surgical procedures.

DATA SOURCES

A comprehensive literature review with evidence-informed recommendations.

REVIEW METHODS

Databases were queried for medical subject heading terms and keywords related to perioperative systemic corticosteroids use for comprehensive otolaryngology and subspecialty procedures including otologic, sinonasal, sleep, laryngeal, head and neck, facial plastics, and pediatric surgery. Perioperative period included preoperative (up to 7 days prior to surgery), intraoperative (on the day of surgery), and postoperative (initiated within 24 hours after surgery) timeframes.

CONCLUSIONS

Evidence from clinical practice guidelines, systematic reviews, and original research studies supports perioperative systemic corticosteroid use for specific otolaryngologic indications. Numerous studies support perioperative steroid use for nausea, vomiting, or edema in tonsillectomy, rhinoplasty, and thyroidectomy, although formal guideline recommendations are limited. Strong evidence supports perioperative steroid use before and after endoscopic sinus surgery for chronic rhinosinusitis with polyposis and fungal sinusitis. Evidence of benefit is sparse or absent on systemic perioperative steroid use for the middle and inner ear, laryngeal, salivary gland surgery, and reconstructive facial plastic surgery.

IMPLICATIONS FOR PRACTICE

Although perioperative administration of systemic steroids is routinely performed for many otolaryngologic surgeries, high-level evidence is limited to specific contexts. Evidence supports the benefit for reducing nausea, vomiting, or edema for several otolaryngologic procedures, as well as for either chronic rhinosinusitis with polyposis or fungal sinusitis. However, these benefits need to be weighed against risks, and further investigations are needed to define the role for perioperative steroids in otolaryngology.

Ablative Versus Conservative Approach for Hyperthyroidism Treatment in Patients with Graves' Orbitopathy: A Retrospective Cohort Study

Background: Treatment for Graves' hyperthyroidism (GH) in patients with Graves' orbitopathy (GO) remains a topic of debate. This study aimed to investigate the outcome of GO following glucocorticoids, depending on the chosen thyroid treatment. Methods: This retrospective cohort study included 49 consecutive patients with GH and moderate-to-severe, active GO, as defined by the European Group on Graves' Orbitopathy guidelines. Twenty-four patients were treated with radioactive iodine (RAI) and 25 with methimazole (MMI). All patients were administered intravenous methylprednisolone. Follow-up visits occurred at weeks 24, 48, and 72. The primary endpoint was the overall outcome of GO at week 24. Response was defined as a change in at least two of the following eye features: reduction ≥1 point in clinical activity score; proptosis reduction ≥2 mm; eyelid aperture reduction ≥2 mm; increase in eye ductions ≥8 degrees. Results: Follow-up duration was 72 weeks for both groups (interquartile range 66-72 for RAI and 48-72 for MMI). The proportion of responders for week 24 overall GO outcome was greater in RAI (54.1% vs. 16%; odds ratio [OR] 6.2 [confidence interval (CI): 1.6-23.6], p = 0.0075), but it increased in MMI at weeks 48 and 72, with no differences between groups. There was a trend indicating a better response in RAI regarding individual eye features. Improvement in GO-specific quality of life questionnaire at week 24 was trendily more pronounced in RAI (responders 50% vs. 28% in MMI; OR = 2.5 [CI: 0.7-8.4], p = 0.11), although results were similar in both groups at later time points. At week 24, only one patient (4%) in RAI and three (12%) in MMI experienced worsening of GO. Fifty-nine adverse events were recorded among 36 patients, with no differences between groups, except for infections, which were more frequent in RAI (53.8% vs. 15.3% in MMI; OR = 6.41 [CI: 1.7-23.9], p = 0.0056). Conclusions: RAI appears to be associated with an earlier response of GO to intravenous glucocorticoids. In the long term, a conservative approach also seems to be effective. RAI appears to be relatively safe when patients are concurrently treated with glucocorticoids. However, randomized clinical trials are necessary to confirm these findings.

Association between clinical activity score and serum sPD-1 and sPD-L1 levels during systemic glucocorticoid treatment for active moderate-to-severe thyroid eye disease

BACKGROUND

CD4+ T lymphocytes are key immune cells involved in orbital inflammation in thyroid eye disease (TED). Inhibition of their activity is important in treatment of TED, but effective drugs targeting these cells are lacking. The programmed cell death-1/programmed cell death ligand-1 pathway has been implicated in several T-cell-mediated diseases. Manipulation of this pathway with antagonists or agonists is an attractive therapeutic option. The role of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) in regulation of this pathway is debated. This study aimed to investigate the involvement of sPD-1 and sPD-L1 in the pathogenesis of TED, focusing on their utility as novel biomarkers to evaluate disease severity and treatment response.

METHODS

Thirty patients diagnosed with moderate-to-severe TED associated with Graves' disease were included. Blood samples were collected from patients before and 12 weeks after initiation of intravenous glucocorticosteroid (IVGC) treatment. Disease severity was assessed using the Clinical Activity Score (CAS) before and after IVGC treatment. Thyroid-stimulating hormone, free thyroxine, free triiodothyronine, thyroid-stimulating immunoglobulin, interleukin-6, sPD-1, and sPD-L1 levels were measured. Correlations between sPD-1, sPD-L1, and CAS before and after IVGC treatment were investigated. Serum concentrations of sPD-1 and sPD-L1 before and after IVGC treatment in patients with TED were compared with those in healthy controls (HCs). The changes in the tested protein concentrations upon IVGC treatment and their associations with clinical characteristics were investigated. Enzyme-linked immunosorbent assays were used to measure sPD-1 and sPD-L1 concentrations in peripheral blood serum.

RESULTS

There was a positive correlation of moderate Spearman's rank strength between sPD-L1 and CAS before and after treatment, and a positive correlation between sPD-1 and sPD-L1. However, no correlation was observed between sPD-1 and CAS. Baseline serum levels of sPD-1 and sPD-L1 did not significantly differ between patients with TED and HCs. There were no correlations between changes in the levels of the tested molecules upon IVGC treatment and the analyzed clinical features. The decreases of sPD-1 and sPD-L1 levels after 12 weeks of IVGC treatment were not significant.

CONCLUSION

The positive correlation of moderate Spearman's rank strength between sPD-L1 and CAS before and after 12 weeks of treatment indicates that sPD-L1 is involved in the pathogenesis of TED. sPD-L1 may become an additional immunological biomarker to assess the disease activity and monitor the respond to treatment. Although sPD-1 is reported in the literature to have an activating effect on lymphocytes, our study shows that sPD-1 may not play a significant role in the pathogenesis of TED, as its level does not differ significantly between the TED and HC groups and does not correlate with disease activity. Understanding the clinical value of sPD-1 and sPD-L1 is of great practical importance.

Evaluation of corticoresistance in patients with thyroid eye disease and use of rituximab as a second-line treatment

PURPOSE

High-dose intravenous glucocorticoids are the standard first-line treatment in active, moderate to severe and severe thyroid eye disease (TED). We evaluate the usefulness of clinical activity score (CAS) and thyroid-stimulating immunoglobulin (TSI) as predictors and/or post-treatment markers of corticoresistance in patients with TED and the effect of rituximab in second-line treatment.

METHODS

We enrolled 236 patients with an active TED into this retrospective single-tertiary-center cohort study. All patients were initially treated with high-dose systemic glucocorticoids. Rituximab was later administered to 29 of 42 corticoresistant patients.

RESULTS

The CAS of the corticoresistant patients was significantly higher both before (p = 0.0001) and after (p = <0.0001) first-line treatment compared to the corticosensitive group. ROC analysis established the cut-point value as CAS ≥ 2.5 with a sensitivity of 96.3%, specificity of 57.5% and area under the curve of 82.8%. In 22 patients treated with rituximab, CAS gradually decreased to zero values without reactivation during extended follow-up. There was no difference in the TSI of corticosensitive and corticoresistant patients before or after first-line therapy.

CONCLUSION

CAS ≥ 2, after first-line treatment, could be used as a corticoresistance marker. Corticoresistant patients should be subject to long-term follow-up for early detection of reactivation to reduce the delay to second-line treatment. Rituximab is a well-tolerated choice of second-line treatment and has a long-lasting effect on disease activity. Although TSI is a valuable biomarker of Graves' disease and TED activity, according to our results, TSI cannot be used as a marker of corticoresistance.

One-Stage Orbital Decompression Combined With Intraoperative Muscle Relaxation for TAO: A Randomized Controlled Trial

PURPOSE

To gauge the efficacy and safety of performing a one-stage endoscopic orbital decompression procedure combined with the intraoperative relaxed medial rectus muscle (MR) positioning technique as a means of treating esotropia associated with thyroid-associated ophthalmopathy (TAO).

DESIGN

Prospective, single-blind, randomized controlled trial.

SETTING

Eye Hospital of Wenzhou Medical University.

METHODS

38 TAO patients fulfilled the study requirements. The patients in Group A (n=19; mean age 52.32 ± 9.90 years; 12 males, 7 females) underwent a one-stage surgical procedure, whereas the patients in Group B (n=19; mean age 52.53 ± 8.49 years; 9 males, 10 females) underwent staged surgery. Preoperative and postoperative best-corrected visual acuity (BCVA), visual field mean deviation (MD), Hertel exophthalmometry, intraocular pressure (IOP), deviation, ocular motility, and diplopia were compared between these two groups.

RESULTS

Of the patients in Group A, 8 (42.11%) underwent unilateral orbital decompression and 11 underwent bilateral decompression, while all 19 patients in Group B underwent bilateral decompression. Both groups exhibited significant improvements in postoperative BCVA (Group A 0.09 ± 0.15 logMAR, Group B 0.04 ± 0.08 logMAR), MD of visual field (Group A -2.73 ± 3.36 dB, Group B -1.82 ± 3.75 dB), proptosis (Group A 16.23 ± 2.58 mm, Group B 17.04 ± 2.70 mm), and IOP (Group A 16.23 ± 4.49 mmHg, Group B 17.24 ± 4.14 mmHg) when comparing postoperative values to preoperative levels, while there were no significant differences between these groups. In each group, 8 patients (42.11%) underwent surgical procedures targeting one single MR, whereas the remaining 11 in each group underwent surgery on two MRs. The respective primary motor and sensory success rates in Group A were 68.40% (13/19) and 78.95% (15/19), whereas those in Group B were 73.70% (14/19) and 84.21% (16/19), with no significant differences between these groups in terms of postoperative residual strabismus, stereoscopic vision improvements, or success rates.

CONCLUSION

These results demonstrate that a one-stage surgical procedure can simultaneously alleviate proptosis and diplopia while achieving outcomes comparable to those achieved through staged surgery. This treatment strategy can thus provide patients with greater therapeutic convenience, decreasing the overall number of surgical procedures and their attendant risks.

Demographic and clinical characteristics of patients with thyroid orbitopathy in a tertiary hospital over 5 years

OBJECTIVE

To describe the demographic and clinical characteristics of thyroid orbitopathy (TO) in a population in Spain.

METHOD

It is a retrospective observational study of patients with TO treated at a tertiary hospital center. We gathered demographic data, ophthalmological symptoms, laterality, symmetry, recurrences, activity according to the Clinical Activity Score scale, severity according to the European Group On Graves' Orbitopathy (EUGOGO), thyroid function and antibody levels. Statistical significance was defined for P values <0.05.

RESULTS

156 patients with TO were included. 128 (82.1%) women, the female/male sex ratio was 4.57:1. The cumulative incidence was 7.47 cases per 100,000 inhabitants/year. The mean age was 50.7 ± 13.2 years. 70 (44.9%) patients were smokers. 62 (39.7%) patients had a family history of thyroid dysfunction. Hyperthyroidism occurred in 90 (57.7%) patients, hypothyroidism in 34 (21.8%) patients, and euthyroidism in 32 (20.5%) patients. Thyroid-stimulating immunoglobulin was elevated in 107 (68.5%) patients. The TO was bilateral in 149 (95.51%) and symmetrical in 99 (66%). Active TO occurred in 28 (17.9%) patients. 110 (70.5%) TO were mild, 41 (26.3%) moderate-severe and 5 (3.2%) very severe. Moderate-severe TO was higher in smokers compared to non-smokers (32.9% vs. 20.9%, p = 0.524).

CONCLUSIONS

TO in our population follows similar patterns to other countries: female sex, mild, bilateral and symmetrical. In smokers, TO may present more severely.

Long-term outcome of Graves' orbitopathy following treatment with sirolimus

OBJECTIVES

Sirolimus was found to be associated with a better outcome of Graves' orbitopathy (GO) at 24 weeks compared to methylprednisolone. We conducted a retrospective study to investigate its efficacy and safety over a longer period.

METHODS

Data from 40 consecutive patients with moderate-to-severe, active GO, 20 treated with sirolimus and 20 with methylprednisolone, were collected.

PRIMARY OUTCOME

overall outcome (composite evaluation) of GO at 48 weeks.

SECONDARY OUTCOMES

(1) GO outcome at 24 weeks, and, at 24 and 48 weeks: (2) outcome of single eye features; (3) quality of life (GO-QoL); (4) TSH-receptor antibodies; (5) GO relapse at 48 weeks; (6) adverse events.

RESULTS

The overall GO outcome at 48 weeks did not differ between the two groups (responders: 55% vs 55%). At 24 weeks, prevalence of responders was greater in sirolimus group (65% vs 25%; P = 0.01). A reduction ≥ 1 point in clinical activity score (CAS) was more frequent in sirolimus patients at 24 (85% vs 40%; P = 0.005) and 48 weeks (75% vs 60%; P = 0.03). The proportion of GO-QoL responders (appearance subscale) at 24 weeks was greater in sirolimus group (62.5% vs 26.3%; P = 0.03). No difference was observed for the remaining outcome measures.

CONCLUSIONS

Treatment with sirolimus is followed by a greater overall response of GO compared with methylprednisolone at 24 weeks, but not at 48 weeks, when only CAS is affected. A more prolonged period of treatment may be required for a better outcome to be observed over a longer period.

The evolution and hotspots of radioactive iodine therapy in hyperthyroidism: a bibliometric analysis

OBJECTIVE

Hyperthyroidism, a prevalent endocrine disorder, disrupts metabolic balance and cardiovascular health, affecting millions globally. Radioactive iodine (RAI), a treatment for hyperthyroidism, employs high-energy beta particles to reduce thyroid tissue, lowering volume and hormone levels. This study utilizes bibliometric analysis to outline RAI's evolution and identify hotspots in hyperthyroidism treatment.

METHODS

A total of 2904 articles and reviews published between 1981 and 2023 were retrieved from the Web of Science Core Collection using the research strategy. Bibliometric analyses, employing VOSviewer and CiteSpace, were performed to visualize the cooperation network, evolution, and hot topics.

RESULTS

Annual publications rose in waves, 2904 papers from 2564 institutions, and 84 countries. The USA led, contributing the largest share, with the journal Thyroid dominating publication. The University of Pisa contributed the most articles. Co-occurrence analysis classified keywords into five clusters: treatment mechanism, safety, effectiveness assessment, individualized radioactive dosage, and management. The development of RAI therapy for hyperthyroidism can be divided into three stages: safety and efficacy assessment, personalized treatment plans, and treatment of drug-resistant and surgery-resistant hyperthyroidism.

CONCLUSION

Attention to RAI in hyperthyroidism should be significantly increased. It is necessary to establish collaborations between authors, countries, and institutions to promote the development of this field. Recent research has focused on personalized radioactive dosage formulation and follow-up. Future studies are likely to concentrate on drug-resistant and surgery-resistant hyperthyroidism, which is also worthy of investigation. These findings provide a new perspective on the study of RAI in hyperthyroidism, potentially contributing to the improvement of the quality of life for patients with hyperthyroidism.

Selenium vs Control for Graves Ophthalmopathy in a Selenium-Sufficient Area: A Randomized Clinical Trial

Importance

Graves ophthalmopathy significantly diminishes patients' quality of life due to its immune-mediated inflammatory effects on the orbital tissues. Selenium, with its antioxidative properties, has shown potential for improving Graves ophthalmopathy progression and quality of life (QOL); however, its effectiveness in selenium-sufficient regions is not well established.

Objective

To determine whether selenium supplementation improves QOL in patients with mild to moderate Graves ophthalmopathy in selenium-sufficient regions.

Design, Setting, and Participants

The Efficacy of Selenium Supplementation for Mild-to-Moderate Graves' Ophthalmopathy in a Selenium-Sufficient Area (SeGOSS) trial was a randomized, open-label multicenter study. Eighty-four patients with mild to moderate Graves' ophthalmopathy were enrolled; 70 completed the study. Participants were selected based on Graves ophthalmopathy diagnosis and sufficient selenium levels. Data were analyzed from October 2023 to March 2024.

Interventions

Participants received selenium supplementation combined with vitamin B complex for 6 months.

Main Outcomes and Measures

The primary outcome was improvements in Graves ophthalmopathy QOL (GO-QOL) scores at 6 months. Secondary outcomes included changes in GO-QOL scores at 3 months, the proportion of patients showing improvement based on GO-QOL scores, clinical activity score, and ophthalmic examinations at 3 months and 6 months, and changes in thyroid autoantibodies at 3 months and 6 months.

Results

There was no improvement in changes in the total GO-QOL scores between the selenium group (31 female patients [83.8%] and 7 male patients [16.2%]; mean [SD] age, 40.8 [11.7] years) and control group (24 female patients [72.7%] and 9 male patients [27.3%]; mean [SD] age, 42.9 [14.2] years) for the primary outcome at 6 months (mean [SD], 12.2 [22.5] vs mean [SD], 11.2 [20.2]; difference, 0.9; 95% CI, -9.3 to 11.3; P = .85). However, at 3 months, a higher proportion of patients in the selenium group showed improved GO-QOL scores compared with the control group (78.4 vs 48.5%; difference, 0.30; 95% CI, 0.08-0.51; P = .01). The selenium group also had higher rates of improvement in proptosis reduction (49.5 vs 15.1%; difference, 0.31; 95% CI, 0.11-0.51; P = .01) at 3 months, though these effects were not sustained at 6 months.

Conclusions and Relevance

These results suggest that selenium supplementation did not improve QOL or clinical parameters in patients with mild to moderate GO in selenium-sufficient regions at 6 months. Some potential QOL benefits noted at 3 months supports consideration of further investigation of selenium for patients seeking treatment for Graves ophthalmopathy .

Trial Registration

Clinical Research Information Service Identifier KCT0004040.

Selenium nutritional status and thyroid dysfunction

Selenium(Se) is an essential micronutrient for several immune and regulatory functions in the body. In thyroid tissue, Se contributes to the antioxidant system and is a crucial component of deiodinases, which are selenoproteins that participate in thyroid hormone metabolism. Additionally, this micronutrient exerts a significant impact on thyroid pathophysiology, as low levels of Se lead to reduced activity of glutathione peroxidase, a selenoprotein involved in antioxidative processes, thereby resulting in increased oxidative stress and damage to thyroid tissue. Selenium deficiency (SeD) can cause growth retardation and reproductive failure; in women and children, it may result in Keshan's disease and Kashin-Beck's disease. Research has shown an inverse correlation between Se serum levels and autoimmune thyroiditis in areas with mild SeD. In Graves' disease, Se supplementation has been linked to faster achievement of euthyroidism as well as improvements in quality of life, lessened orbital involvement, and slower ocular progression of the disease. Furthermore, several studies suggest an association between serum SeD and the development of thyroid cancer. Maintaining physiological Se concentrations appears to be related to the prevention of thyroid disease, although current data are insufficient to conclusively support or refute the efficacy of supplementation. Through this narrative review, we aim to present the latest information on the role of selenium in thyroid pathophysiology. To identify relevant literature, specific search strategies were employed in the electronic databases PubMed, Lilacs, and SciELO.

Correlation Between Changes in Extraocular Muscles and Intraocular Pressure Following Anti-Inflammatory Therapy in Active Thyroid Eye Disease

Objectives: We investigate the correlation between functional and morphological changes in extraocular muscles (EOMs) and intraocular pressure (IOP) changes before and after thyroid eye disease (TED) treatment. Methods: A multicenter study with a retrospective chart review was conducted. Patients with active TED receiving corticosteroid therapy without glaucoma eye drops between 2014 and 2023 were reviewed. Various parameters were measured by magnetic resonance imaging. The primary outcome measure was the correlation between changes in the IOP and the cross-sectional area (CSA) of the EOMs before and after treatment. Secondary outcome measures were comparisons of IOP, the signal intensity ratio (SIR) of the EOMs and orbital fatty tissue (OFT), and the CSA of the EOMs before and after treatment. Results: The IOP in 99 eyes in 51 patients significantly decreased from 18 ± 3.4 mmHg to 15.5 ± 2.9 mmHg before and after treatment (p < 0.01)). The CSA and SIR of all EOMs and OFT significantly decreased after treatment (p < 0.05). Factors that had a significant positive correlation with the IOP change rate before and after treatment were the CSA change rate of the inferior rectus muscle (IRM) before and after treatment (Spearman's correlation coefficient, R2 = 0.24, p < 0.05) and the CSA change rate of the total EOMs before and after treatment (Spearman's correlation coefficient, R2 = 0.22, p < 0.05). Conclusions: In TED patients, IOP decreased with anti-inflammatory treatment alone. The most significant parameter that correlated with the decrease in IOP was the CSA change rate of the IRM.

Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Autoimmune Diseases

Autoimmune diseases are characterized by immune dysregulation, resulting in aberrant reactivity of T cells and antibodies to self-antigens, leading to various patterns of inflammation and organ dysfunction. However, current therapeutic agents exhibit broad-spectrum activity and lack disease-specific selectivity, leading to enduring adverse effects, notably severe infections, and malignancies, and patients often fail to achieve the intended clinical goals. Mesenchymal stromal cells (MSCs) are multipotent stromal cells that can be easily derived from various tissues, such as adipose tissue, umbilical cords, Wharton's jelly, placenta, and dental tissues. MSCs offer advantages due to their immunomodulatory and anti-inflammatory abilities, low immunogenicity, and a high capacity for proliferation and multipotent differentiation, making them excellent candidates for cell-based treatment in autoimmune disorders. This review will cover preclinical studies and clinical trials involving MSCs in autoimmune diseases, as well as the primary challenges associated with the clinical application of MSC therapies and strategies for maximizing their therapeutic potential.

Graves ophthalmopathy a neglected comorbidity of graves' disease; a detailed investigation and management of sixty-eight patients in a tertiary healthcare center

PURPOSE

To compare the measurements of macular thickness, intraocular pressure and RNFL and hormone parameters before and after antithyroid therapy in patients with Graves' Ophthalmopathy (GO).

METHODS

A prospective observational study conducted at a tertiary care center. Patients with GO were included and scored (Clinical Activity Score, CAS) according to EUGOGO guideline. The participants underwent extensive ophthalmological examinations including intraocular pressure measurements with Goldmann applanation tonometry and RNFL with macular thickness evaluations via optical coherence tomography (OCT). Baseline and follow-up (24 weeks) hormone parameters including free T3, free T4, Thyroid stimulating hormone (TSH), Thyroid receptor autoantibodies (TRAbs) and intraocular measurements (RNFL, macular thickness, intraocular pressure) were performed and compared in the current study.

RESULTS

Comparisons of baseline and follow-up biochemical parameters TSH, fT3, fT4, TRAbs, anti-TPO (p < 0.001). Although baseline score of CAS was mildly increased in all patients (0.5 ± 0.8 vs. 0.1 ± 0.4, p < 0.001) but it was significantly decreased after the antithyroid therapy. Mean intraocular pressure (14.9 ± 2.8 vs. 14.2 ± 1.9), RNFL (100.2 ± 9.05 vs. 99.9 ± 8.7) and macular thickness (274.7 ± 42.9 vs. 271.2 ± 43.3) were similar between baseline and after antithyroid therapy. And baseline RNFL measurements showed significant negative correlation with serum baseline TRAbs, antiTPO, fT3, fT4 (p < 0.05).

CONCLUSION

Baseline serum fT3, fT4 and TRAbs in patients with Graves' Disease levels may be the prognostic factors in the evaluation of affecting intraocular structure, especially Retinal Nerve Fiber Layer, in patients with GO.

CT-Based Machine Learning Radiomics Analysis to Diagnose Dysthyroid Optic Neuropathy

PURPOSE

To develop CT-based machine learning radiomics models used for the diagnosis of dysthyroid optic neuropathy (DON).

MATERIALS AND METHODS

This is a retrospective study included 57 patients (114 orbits) diagnosed with thyroid-associated ophthalmopathy (TAO) at the Beijing Tongren Hospital between December 2019 and June 2023. CT scans, medical history, examination results, and clinical data of the participants were collected. DON was diagnosed based on clinical manifestations and examinations. The DON orbits and non-DON orbits were then divided into a training set and a test set at a ratio of approximately 7:3. The 3D slicer software was used to identify the volumes of interest (VOI). Radiomics features were extracted using the Pyradiomics and selected by t-test and least absolute shrinkage and selection operator (LASSO) regression algorithm with 10-fold cross-validation. Machine-learning models, including random forest (RF) model, support vector machine (SVM) model, and logistic regression (LR) model were built and validated by receiver operating characteristic (ROC) curves, area under the curves (AUC) and confusion matrix-related data. The net benefit of the models is shown by the decision curve analysis (DCA).

RESULTS

We extracted 107 features from the imaging data, representing various image information of the optic nerve and surrounding orbital tissues. Using the LASSO method, we identified the five most informative features. The AUC ranged from 0.77 to 0.80 in the training set and the AUC of the RF, SVM and LR models based on the features were 0.86, 0.80 and 0.83 in the test set, respectively. The DeLong test showed there was no significant difference between the three models (RF model vs SVM model: p = .92; RF model vs LR model: p = .94; SVM model vs LR model: p = .98) and the models showed optimal clinical efficacy in DCA.

CONCLUSIONS

The CT-based machine learning radiomics analysis exhibited excellent ability to diagnose DON and may enhance diagnostic convenience.

The Efficacy and Safety of Intravenous Tocilizumab to Treat Graves' Ophthalmopathy: A Systematic Review and Single-arm Meta-analysis

PURPOSE

This study aims to evaluate the efficacy and safety of intravenous (IV) tocilizumab (TCZ) in the treatment of Graves' ophthalmopathy (GO).

METHODS

A comprehensive search was conducted across the Web of Science, PubMed, Embase, Cochrane Library, World Health Organization International Clinical Trials Registry Platform, and ClinicalTrials.gov databases from inception to April 2024. Randomized controlled trials and cohort studies that used IV TCZ for treating GO were included.

RESULTS

Twelve studies encompassing 219 patients with active, steroid-resistant GO were analyzed. The meta-analysis demonstrated significant improvements in Clinical Activity Score (CAS) response (effect size [ES] = 0.98; 95% confidence interval [CI], 0.93-1.00), proptosis response (ES = 0.50; 95% CI, 0.27-0.73), and diplopia response (ES = 0.48; 95% CI, 0.24-0.74). The ES for adverse events was 0.27 (95% CI, 0.22-0.33), with only 3 severe cases necessitating treatment discontinuation, and a low reactivation rate (ES = 0.01; 95% CI, 0.00-0.04). TCZ treatment led to a mean CAS reduction of 4.60 points (95% CI, 3.88-5.32) across 10 studies, a mean proptosis reduction of 2.04 mm (95% CI, 1.42-2.65) across 7 studies, and a mean decrease in TSH receptor antibodies levels of 10.62 IU (95% CI, 4.67-10.62) across 5 studies.

CONCLUSION

This meta-analysis provides robust evidence supporting the efficacy and safety of IV TCZ in patients with GO who are resistant to glucocorticoid therapy. The results highlight TCZ's comparable efficacy to glucocorticoids and suggest that TCZ could significantly expand clinical management options for GO. In the future, more high-quality, large-scale randomized controlled trials are still needed to confirm these findings.

Orbital Radiotherapy for Graves' Ophthalmopathy: Single Institutional Experience of Efficacy and Safety

Graves' ophthalmopathy is the most common extrathyroidal manifestation of Graves-Basedow disease. Radiotherapy is effective especially when used in synergy with the administration of glucocorticoids. The aim of our study was to analyze the effectiveness and safety of radiotherapy, using different protocols, to improve ocular symptoms and quality of life.

METHODS

We retrospectively analyzed the clinical data of two-hundred and three patients treated with retrobulbar radiotherapy between January 2002 and June 2023. Ninety-nine patients were treated with a schedule of 10 Gy in 10 fractions and one-hundred and four were treated with 10 Gy in 5 fractions. Radiotherapy (RT) was administrated during the 12 weeks of pulse steroid therapy. Patients were evaluated with a clinical exam, orbital CT, thyroid assessment, and Clinical Activity Score (CAS).

RESULTS

The median follow-up was 28.6 months (range 12-240). Complete response was found in ninety-four pts (46.31%), partial response or stabilization in one hundred pts (49.26%), and progression in nine pts (4.43%). In most subjects, an improvement in visual acuity and a reduction in CAS of at least 2 points and proptosis by more than 3 mm were observed. Three patients needed decompressive surgery after treatment. Only G1 and G2 acute eye disorders and no cases of xerophthalmia or cataract were assessed.

CONCLUSIONS

RT is an effective and well-tolerated treatment in this setting, especially when associated with the administration of glucocorticoids. Although the most used fractionation schedule in the literature is 20 Gy in 10 fractions, in our clinical practice, we have achieved comparable results with 10 Gy in 5 or 10 fractions with a lower incidence of toxicity.

PDK2-enhanced glycolysis aggravates fibrosis via IL11 signaling pathway in Graves' orbitopathy

Objectives

Transforming growth factor β1 (TGFβ1)-interleukin 11 (IL11) is a newly found critical signaling pathway in fibrotic diseases such as Graves' orbitopathy (GO). It has now been confirmed that enhanced glycolysis plays a key role in the pathogenesis of GO. However, little is known about the relationship between glycolysis and IL11-mediated fibrosis in GO. This study aimed to identify the relationship between glycolysis and TGFβ1-IL11 signaling pathway and investigate the role of IL11 in glycolysis-facilitated fibrosis in GO.

Methods

Orbital connective tissues were collected from GO and control patients. Primary orbital fibroblasts (OFs) were cultured from clinical tissues. Patient-derived xenografts were established via intraorbital transplantation of GO orbital tissue in humanized NCG mice. Protein levels were measured using Capillary Western Immunoassay (WES). Small interfering RNA (siRNA) was used to construct transfected OF strains. Lactate production was measured to assess glycolysis status. Animal models were assessed by T2-weighted magnetic resonance (MR) scan. Immunohistochemistry staining was applied to patients' orbital connective tissues.

Results

Orbital connective tissues were collected from GO patients. Immunohistochemical (IHC) staining of GO tissues revealed the phenomenon of pyruvate dehydrogenase kinase 2 (PDK2)-enhanced glycolysis and upregulated IL11-IL11Rα pathway. In vitro experiments showed successful induction of fibrosis of patient-derived orbital fat/connective tissues, which could be alleviated by dichloroacetic acid (DCA). MRI images and analysis of hematoxylin and eosin (HE) and Masson-stained section demonstrated enhanced glycolysis in GO, facilitating fibrosis of the orbital tissue. Targeting PDK2 decreased IL11 expression to suppress fibrosis. In vivo experiment confirmed anti-fibrotic effect of inhibition of glycolysis.

Conclusions

PDK2-enhanced glycolysis exacerbates fibrosis via IL11-IL11Rα signaling pathway, shedding light on a potential therapeutic role of metabolic modulators such as DCA in GO treatment.

De novo Graves' thyroid eye disease after radioiodine treatment for toxic nodular thyroid disease

It is well known that radioactive iodine treatment (RAI) for thyrotoxicosis in Graves' disease can precipitate worsening of thyroid eye disease (TED), particularly in susceptible patients. Less commonly, it has been associated with de novo development of TED in those with Graves' disease without a history. Prophylactic steroid treatment has been shown to reduce the incidence of this phenomenon in those with risk factors.Here, we describe a patient with thyrotoxicosis due to nodular thyroid disease rather than Graves' disease and normal baseline thyroid-stimulating hormone receptor antibody (TRAb) levels and no other risk factors for TED, who subsequently developed new onset TED associated with thyrotoxicosis and elevated TRAb levels following RAI.

Extranodal natural killer/T-cell lymphoma with secondary haemophagocytic lymphohistiocytosis simulating orbital inflammatory disease

This case report describes an uncommon case of periorbital swelling due to a rare neoplastic condition, a natural killer/T-cell lymphoma, which presented a significant diagnostic challenge. The malignancy was complicated by hemophagocytic lymphohistiocytosis that led to mortality within a month of initial presentation.

Intravenous methylprednisolone-induced hypokalaemic periodic paralysis in a thyrotoxic patient: a case report and literature review

Hypokalaemic periodic paralysis (HPP) is an uncommon complication of corticosteroid therapy, which may also be seen in thyrotoxicosis. It was mostly described in the Asian population, and it is rare in other ethnic groups. We present the case of a poorly controlled thyrotoxic Caucasian male with thyroid eye disease (TED) who suffered an acute quadriplegic episode caused by severe hypokalaemia and was admitted to the intensive care unit (ITU) within 24 hours of initiating intravenous methylprednisolone (IVMP) infusion. Once his potassium blood levels were repleted, he completely recovered from the episode. Although HPP is rare in the Caucasian population, it can be precipitated in thyrotoxic patients by systemic steroids. Caution should be exercised when administering IVMP in poorly controlled thyrotoxic patients, and we suggest monitoring the potassium levels at regular intervals with ECG monitoring for at least 24 hours in at-risk individuals.

The selection of target areas for orbital imaging, application of diethylenetriaminepentaacetic acid orbital imaging, clinical factors, alkaline phosphatase, and thyrotropin receptor antibodies in the staging and grading of thyroid-associated ophthalmopathy

PURPOSE

This study aimed to investigate the active phase of thyroid-associated ophthalmopathy (TAO), its correlations with clinical factors, serological tests, and orbital imaging parameters, and evaluate the diagnostic value of different orbital imaging target areas.

METHODS

A total of 45 patients with thyroid-related eye disease underwent imaging, serological tests, and clinical data collection. Clinical Activity Score (CAS) assessment, diplopia scores, and NOSPECS grading were conducted. Radioactive counts of extraocular muscles and tear glands were measured. Computed tomography scans assessed exophthalmos and extraocular muscle thickening. Correlations and differences among study parameters and grades were evaluated using receiver operating characteristic curves.

RESULTS

Active TAO correlated significantly with radioactive counts of muscles and tear glands, alkaline phosphatase (ALP), thyrotropin receptor antibody (TRAb), and age. Significant differences were found among NOSPECS grades for studied variables (except ALP and TRAb). Extraocular muscle thickening was confirmed as a reliable diagnostic criterion. High consistency was found between orbital imaging and CAS staging. Treatment showed varying degrees of improvement in active patients, while nonactive patients showed no progression during follow-up. Receiver operating characteristic curves demonstrated high diagnostic efficacy for tear gland radioactive counts.

CONCLUSION

Tear glands and extraocular muscles have high diagnostic value in TAO, with tear glands showing a higher value. Orbital imaging provides an objective and comprehensive assessment compared with CAS scoring alone. ALP, TRAb, and age also play significant roles in staging.

Statin Use and the Risk of Graves' Orbitopathy: A Nationwide Population-Based Cohort Study

Background: Statin use is reported to reduce the risk of Graves' orbitopathy (GO) in Western populations. However, study regarding the protective effect of statins against GO in Asians with Graves' disease (GD) is scarce. This study aims to investigate the efficacy of statins in preventing GO in Asian GD patients. Materials and Methods: This nationwide, population-based retrospective cohort study used data from beneficiaries aged >40 years diagnosed with GD from the National Health Insurance Research Database (NHIRD) from 2010 to 2020. The International Classification of Diseases codes, Anatomical Therapeutic Chemical codes, and the surgery/procedure codes derived from the NHIRD were used to obtain the information on GD, GO, and statin use. Propensity score (PS) analysis with matching and inverse probability of treatment weighting analysis (IPTW) was conducted to minimize confounding. The Kaplan-Meier survival analysis and multivariable Cox regression analysis were used to compare the risk of GO among statin users and nonusers. Results: The final analysis included 102,858 patients; 7,073 were statin users (62.9 ± 10.6 years, 29.7% male), and 95,785 were nonusers (53.6 ± 10.4 years, 25.7% male). The crude incidence rate of GO among statin users and nonusers was 5.00‰ versus 6.75‰ and 4.91‰ versus 5.15‰ for the overall population and population after PS matching method, respectively. The Cox regression analysis showed that statin users had a significantly lower risk of GO (adjusted hazard ratio [HR] after PS matching 0.79, 95% confidence interval [CI]: 0.63-0.99, p = 0.037; adjusted HR after IPTW method: 0.64, CI: 0.51-0.79, p < 0.001). The risk of GO was not different among users of different kinds of statins (i.e., atorvastatin, rosuvastatin, pitavastatin, and other statins) or among different intensities of statins (low-to-moderate intensity vs. high intensity). Conclusions: The use of statins in Asian GD patients was associated with a reduced risk of GO. In addition, the risk of developing GO among users of commonly prescribed statins or users of different intensities of statins was not significantly different.

Evaluation of Inflammatory Activity of Extraocular Muscles in Thyroid Associated Orbitopathy by [68Ga]DOTATATE PET/CT

PURPOSE

The accurate assessment of inflammatory activity of the extraocular muscles (EOMs) in thyroid associated ophthalmopathy (TAO) is crucial for formulating subsequent treatment strategies and prognostic judgments. This study aims to explore the efficacy of using [68Ga]DOTATATE PET/CT to assess the inflammatory activity of EOMs in TAO patients.

PROCEDURES

This study enrolled 22 TAO patients and 6 healthy volunteers, all of whom underwent orbital [68Ga]DOTATATE PET/CT. Among these, 18 patients underwent orbital [99mTc]DTPA SPECT/CT within one week, and the other 4 patients received orbital MRI. All imaging data were independently assessed, followed by comparative data analysis. The patients then received different treatment schemes, and their prognosis was followed up.

RESULTS

[68Ga]DOTATATE PET/CT could effectively evaluate the inflammatory activity of the EOMs in TAO patients and demonstrate good consistency with [99mTc]DTPA SPECT/CT and orbital MRI, but show a better resolution to distinguish EOMs and surrounding structure. The receiver operating characteristic (ROC) curves for each EOM, treated as individual research units, exhibited an area under the curve (AUC) exceeding 0.9. The medial rectus demonstrated the highest involvement and diagnostic accuracy(AUC = 0.976, P < 0.001). Patients treated with glucocorticoids showed significantly higher SUVmax in EOMs compared to those receiving symptomatic treatment (P < 0.01).

CONCLUSIONS

[68Ga]DOTATATE PET/CT is a reliable method for assessing the inflammatory activity of EOMs in TAO patients, providing strong objective evidence for the precise diagnosis and treatment.

Elucidating the pharmacological foundations and mechanisms of the Sihai Shuyu formula in treating Graves' disease through integrated serum metabolomics and network pharmacology with molecular docking techniques

Ethnopharmacological relevance

The Sihai Shuyu Formula (SHSY) shows promising potential for treating Graves' disease (GD), although the therapeutic mechanisms and pharmacological basis of SHSY have not been thoroughly evaluated.

Objective

This work is aim to investigate the pharmacological basis and mechanism of SHSY in the treatment of GD by integrating non-targeted serum metabolomics and network pharmacology coupled with molecular docking technology.

Materials and methods

GD was induced in mice through injections of Ad-TSH289. Treatments included methimazole, inorganic iodine, and both low and high doses of SHSY administered via gavage. At the end of the treatment period, serum levels of thyroxine (T4) and thyrotropin receptor antibody (TRAb) were measured. Hematoxylin-Eosin (H&E) staining assessed the effects of these pharmacological interventions on thyroid gland tissues. Ultra-High Performance Liquid Chromatography with Quadrupole Time-of-Flight Mass Spectrometry (UPLC-Q-TOF-MS) was used in conjunction with network pharmacology and molecular docking to identify and predict SHSY's active chemical components and targets. A comprehensive analysis of the multi-level bioinformatic analysis, including protein-protein interactions (PPI) and functional pathways of the targets, was conducted, followed by verification through immunohistochemistry (IHC) to clarify SHSY's pharmacological basis and action mechanisms in treating GD.

Results

After 8 weeks of treatment, SHSY significantly reduced serum T4 and TRAb levels in GD mice and enhanced the morphology of thyroid tissues. Comparative analysis of rat blood samples and SHSY using UPLC-Q-TOF-MS identified 19 blood-entry components, the potential active components of SHSY acting on GD. Further network pharmacological analysis indicated that SHSY targets the PI3K/Akt signaling pathway through components such as PIK3CD, SRC, PIK3CA, HRAS, EGFR, PIK3R1, AKT1, PTPN11, and PIK3CB. Molecular docking confirmed the effective binding of SHSY's components to these targets. IHC confirmed that the IGF1R/PI3K/Akt signaling pathway is a significant therapeutic target of SHSY, with key substances including Guggulsterone, Betulinic aldehyde, and Forsythoside H.

Conclusions

SHSY appears to effectively treat GD through the IGF1R/PI3K/Akt signaling pathway, with Guggulsterone, Betulinic aldehyde, and Forsythoside H as the critical pharmacological components. It may serve as an adjunctive treatment for GD alongside traditional therapies such as antithyroid medications, surgery, and radioiodine therapy.

A curative effect evaluation of intensity-modulated radiation therapy combined with periorbital triamcinolone acetonide injection in treating thyroid eye disease patients with active extraocular muscle but low CAS

The purpose of this study is to evaluate the effectiveness of intensity-modulated radiation therapy (IMRT) combined with periorbital triamcinolone acetonide injection in treating thyroid eye disease (TED) patients with active extraocular muscle but low CAS. The retrospective observational study was conducted. A total of 156 eligible patients were selected from the TED patient database of the Ophthalmology Department of West China Hospital of Sichuan University. The patient's relevant medical history was recorded, including gender, age of initial onset, onset eye, the interval between onset and the first visit to our hospital, extraocular muscle condition, smoking status, CAS, NOSPECS, thyroid function, symptoms and signs, and the condition of the affected extraocular muscle. We found that IMRT combined with periorbital triamcinolone acetonide injection has a good therapeutic effect on TED patients with low CAS but significant active extraocular muscles, and there is a significant improvement at 3 months after treatment. Thyroid function and CAS can affect the curative effect of IMRT. Patients with hyperthyroidism had worse effect than those with normal thyroid function. The higher the CAS, the better the effect.

Tocilizumab - a disease-modulating treatment for thyroid associated ophthalmopathy?

PURPOSE

To analyze Tocilizumab (TCZ, an interleukin 6 inhibitor) as a second-line treatment for thyroid-associated ophthalmopathy (TAO).

METHODS

In this retrospective observational study, the charts of patients with moderately severe to severe TAO who received intravenous Tocilizumab as a second-line treatment 2020-2023 were reviewed.

RESULTS

Twenty-three patients were enrolled in the study. At the follow-up visit 24 weeks after the initiation of treatment, 14 out of 22 patients (63.6%, one missing data) had a reduction of proptosis of 2 mm or more. The mean proptosis decreased from 21.07 (±3.23) to 19.18 (±2.52) mm in the right eye (RE) and from 20.61 (±3.12) to 19.95 (±2.81) mm in the left eye (LE). Twenty patients (87%) also showed a reduction of the clinical activity score (CAS) of at least two points with a mean decrease from 5.22 (±1.53) pre-treatment to 2.09 (±1.38) post-treatment points. The median patient total follow-up time after treatment was ten (range 6-26) months. The comparisons reached strong significance between pre-treatment and 24 weeks, as well as pre-treatment and final visit assessments for both proptosis and clinical activity scores. Serum TRAb levels also dropped significantly, and only two patients needed re-treatment with TCZ. Improvement of diplopia did not reach statistical significance.

CONCLUSIONS

Intravenous Tocilizumab as a second-line treatment for TAO led to a significant improvement of proptosis and CAS at 24 weeks follow-up, with a sustained effect over time.

Effects of Trace Elements on Endocrine Function and Pathogenesis of Thyroid Diseases-A Literature Review

The thyroid gland is an endocrine organ whose hormones enable the proper functioning of the organism. The normal function of this organ is influenced by internal and external factors. One of the external factors is trace elements. Trace elements in appropriate concentrations are necessary for the proper functioning of the thyroid. Fe, Cu, Mn, I, Zn, and Se are part of the enzymes involved in oxidative stress reduction, while Cd, Hg, and Pb can increase ROS production. Cu and Fe are necessary for the correct TPO synthesis. An imbalance in the concentration of trace elements such as Fe, Cu, Co, I, Mn, Zn, Ag, Cd, Hg, Pb, and Se in thyroid cells can lead to thyroid diseases such as Graves' disease, Hashimoto's thyroiditis, hypothyroidism, autoimmune thyroiditis, thyroid nodules, thyroid cancer, and postpartum thyroiditis. Lack of adequate Fe levels may lead to hypothyroidism and cancer development. The thyroid gland's ability to absorb I is reversibly reduced by Co. Adequate levels of I are required for correct thyroid function; both deficiency and excess can predispose to the development of thyroid disorders. High concentrations of Mn may lead to hypothyroidism. Furthermore, Mn may cause cancer development and progression. Insufficient Zn supplementation causes hypothyroidism and thyroid nodule development. Cd affecting molecular mechanisms may also lead to thyroid disorders. Hg accumulating in the thyroid may interfere with hormone secretion and stimulate cancer cell proliferation. A higher risk of thyroid nodules, cancer, autoimmune thyroiditis, and hypothyroidism were linked to elevated Pb levels. Se deficiency disrupts thyroid cell function and may lead to several thyroid disorders. On the other hand, some of the trace elements may be useful in the treatment of thyroid diseases. Therefore, the effects of trace elements on the thyroid require further research.

Novel perspectives on the pharmacological treatment of thyroid-associated ophthalmopathy

Thyroid-associated ophthalmopathy (TAO), an autoimmune disease closely related to thyroid dysfunction, remains a challenging ophthalmic condition among adults. Its clinical manifestations are complex and diverse, and disease progression can lead to exophthalmos, diplopia, exposure keratitis, corneal ulceration, and compressive optic neuropathy, resulting in irreversible vision damage or even blindness. Traditional treatment methods for TAO, including glucocorticoids, immunosuppressants, and radiation therapy, often have limitations and side effects, making this disease problematic in ophthalmology. As a result, the development of novel targeted drugs has become a research hotspot for addressing the pathogenesis of TAO. A range of novel targeted drugs, such as teprotumumab and tocilizumab, have been successfully developed and demonstrated remarkable efficacy in relieving inflammation and managing this disease. In addition, some drug candidates and molecular targets identified in the TAO in vitro model have shown promising prospects. This article briefly reviews the potential new strategies for future clinical treatment and the progress of new drug therapies for TAO.

TOM500: A Multi-Organ Annotated Orbital MRI Dataset for Thyroid Eye Disease

This study presents TOM500, a comprehensive multi-organ annotated orbital magnetic resonance imaging (MRI) dataset. It includes clinical data, T2-weighted MRI scans, and corresponding segmentations from 500 patients with thyroid eye disease (TED) during their initial visit. TED is a common autoimmune disorder with distinct orbital MRI features. Segmentations of nine orbital structures, including the optic nerve, orbital fat, lacrimal gland, eyeball, and five extraocular muscles (superior rectus and levator palpebrae superioris complex, inferior rectus, medial rectus, lateral rectus, and superior oblique), were generated by three junior annotators and reviewed by an expert radiologist. The consistency of the segmentations was evaluated using the intraclass correlation coefficient. Clinical data, including sex, age, disease duration, and smoking status, are also provided for disease diagnosis and classification. TOM500, the largest publicly available orbital MRI dataset with expert annotations, is designed to facilitate the development of advanced computational tools for TED diagnosis, classification, and observation.

Altered static and dynamic spontaneous brain activity in patients with dysthyroid optic neuropathy: a resting-state fMRI study

Purpose

To investigate static and dynamic brain functional alterations in dysthyroid optic neuropathy (DON) using resting-state functional MRI (rs-fMRI) with the amplitude of low-frequency fluctuation (ALFF) and regional homogeneity (ReHo).

Materials and methods

Fifty-seven thyroid-associated ophthalmopathy (TAO) patients (23 DON and 34 non-DON) and 27 healthy controls (HCs) underwent rs-fMRI scans. Static and dynamic ALFF (sALFF and dALFF) and ReHo (sReHo and dReHo) values were compared between groups. The support-vector machine (SVM) classification method was used to examine the diagnostic performance of the identified models.

Results

Compared to non-DON patients, DON patients showed decreased sALFF in the bilateral lingual gyrus (LING) and right cuneus (CUN), alongside increased sALFF in the bilateral medial part of the superior frontal gyrus, right dorsolateral part of the superior frontal gyrus (SFGdor), and right precentral gyrus. DON patients also exhibited decreased dALFF in the left LING and right CUN, together with increased dALFF in the right orbital part of the middle frontal gyrus and right SFGdor in comparison to non-DON patients. Meanwhile, DON patients had lower sReHo in the right LING, and higher sReHo and dReHo in the right supramarginal gyrus compared to non-DON patients. When detecting DON, the dALFF model showed optimal diagnostic performance (AUC 0.9987).

Conclusion

Dysthyroid optic neuropathy patients exhibited both static and dynamic brain functional alterations in visual, cognitive, and emotion-related brain regions, deepening our current understanding of the underlying neural mechanisms of this disease. Rs-fMRI-based metrics, especially dALFF, may serve as relevant neuroimaging markers for diagnosing DON.

Analytical validation of a novel bioassay for thyroid-stimulating immunoglobulin

Background

A novel and rapid cell-based bioassay, Turbo TSI, for measurement of thyroid-stimulating immunoglobulins (TSI) was recently reported. An assessment of the analytical performance of this TSI bioassay is described herein.

Methods

Thawed cells from Turbo TSI kits were treated with different concentrations of a World Health Organization (WHO) international standard (IS) TSI-positive serum. TSI was measured as a function of luciferase activity measured as relative light units (RLU) and converted into international units per liter (IU/L). Analytical performance studies were performed on numerous samples, over multiple days, by two users at two sites.

Results

The limit of blank, limit of detection and limit of quantitation were determined to be 0.007 IU/L, 0.014 IU/L, and 0.021 IU/L, respectively. Receiver operator characteristics (ROC) analysis determined the cut-off to be 0.0241 IU/L with an area under the curve of 0.984. The linear range was shown to be from 0.015 to 11.958 IU/L. The intra-laboratory precision was ≤15%CV. The overall reproducibility of the assay was ≤20%CV for five concentrations (0.06 to 5.16 IU/L). Interference and cross reactivity studies with a variety of substances showed that the assay was robust. The Turbo TSI bioassay demonstrated 95.2% (95% CI 83.3-98.1) positive percent agreement and 94.8% (95% CI 90.9-97.1) negative percent agreement with an FDA-cleared bioassay (Thyretain ® TSI) using serum from 295 patients with autoimmune thyroid disease.

Conclusions

The Turbo TSI bioassay exhibits excellent analytical performance and a high level of reproducibility. The performance compared well with Thyretain ® TSI, an FDA-cleared TSI bioassay.

Elimination of oral foci of infection might lead to clinical improvement of Graves' orbitopathy

PURPOSE

Graves' disease (GD) and Graves' orbitopathy (GO) are multifactorial disorders with links to the gut microbiome and autoimmunity. It is observed that patients with GD exhibit altered gut microbiome diversity. However, little is known about the role of oral microbiota in GD and GO. This study aims to investigate the impact of oral health and oral sanitation on the clinical course of GO in patients disqualified from glucocorticoid treatment due to oral infections.

METHODS

We reviewed 188 admissions of 127 patients with GO, hospitalized in a tertiary university hospital. Clinical, biochemical, imaging, ophthalmological, and oral health assessment data from each admission were analyzed. Patients excluded from the glucocorticoids (GCs) therapy due to oral foci of infection had the clinical activity score (CAS) reassessed after three months, and they were divided into two groups: with and without improvement.

RESULTS

Finishing dental treatment in the meantime was the only factor significantly correlated with improvement in these patients (p = 0.041). The secondary finding was that anti-thyroid peroxidase antibodies titer was significantly higher in the group with oral foci of infection considered as a contraindication for GCs (medians 28.50 vs 128.00; p = 0.026), and those patients were more likely to smoke than the group without oral issues (p = 0.024).

CONCLUSIONS

The results of our study suggest that monitoring and treating oral diseases may be pertinent in patients with GO and might serve as a supportive treatment strategy for managing the condition.

KEY MESSAGES

What is known: There is a recognized link between gut dysbiosis and the autoimmune processes in Graves' Disease (GD) and Graves' Orbitopathy (GO).

WHAT IS NEW

Elevated levels of TPOAb have been observed in patients with GO who also have oral foci of infection. Dental treatment has been shown to lead to significant clinical improvements in patients with GO. Maintaining oral hygiene might serve as a supportive treatment strategy for managing GO.

[Survey of the management of moderate to severe active Graves' orbitopathy at 28 metropolitan centers of excellence in France]

INTRODUCTION

This study investigates the management of Graves'orbitopathy (GO) in France, at 26 university medical centers (CHU) as well as the Rothschild Foundation and the Quinze-Vingts national eye hospital in Paris.

METHODS

The 28 metropolitan university medical centers were contacted by telephone or e-mail. The authors devised a 5-item questionnaire that explored the scheduling of multidisciplinary meetings, the existence or lack of a dedicated Graves' consultation service, the place of hospitalization, and first- and second-line treatments.

RESULTS

Eighty-nine percent of hospital departments had a dedicated service for patients with GO, with 36% organizing multidisciplinary meetings. Intravenous corticosteroid therapy is still used as first-line treatment, while mycophenolate is used much less (14.3%), despite the new EUGOGO (European Group on Graves' orbitopathy) 2021 recommendations. For second-line treatment, tocilizumab is most commonly used (64%). Teprotumumab is available in France only on a compassionate basis, and its use is limited (18%).

CONCLUSION

This study highlights the variability in practices and the importance of a multidisciplinary approach, while calling for national standardization of practices. Despite disparities in the application of recommendations, the emergence of second-line treatments such as tocilizumab and teprotumumab indicates a steady evolution in therapeutic options, although obstacles in terms of accessibility and cost remain.

Histogram of Apparent Diffusion Coefficient to Evaluate the Activity of Thyroid-Associated Ophthalmopathy

OBJECTIVE

This study aimed to evaluate the activity of extraocular muscles (EOMs) in patients with thyroid-associated ophthalmopathy (TAO) using turbo spin echo imaging. By analyzing tissue heterogeneity, apparent diffusion coefficient (ADC) histogram analysis offers enhanced insights into edema within the EOMs.

METHODS

Eighty-eight patients with TAO were retrospectively evaluated and allocated into active (n = 24, clinical activity score [CAS] ≥ 3) and inactive (n = 64, CAS < 3) groups. The parameter values of the ADC histogram of EOMs were measured; the efficacy of ADC histograms in distinguishing between TAO activity and inactivity was assessed using receiver operating characteristic curves. Multifactorial logistic regression was used to determine active TAO predictors.

RESULTS

The minimum, maximum, median, mean; and 1st, 5th, 10th, 25th, 75th, 90th, 95th, and 99th percentiles of the ADC histograms were higher in patients with active than that in participants with inactive TAO. The area under the curve (AUC) of the 10th percentile of the ADC histogram and the median distinguishing between active and inactive TAOs were both 0.791 (both p < 0.05), and the AUCs of the combined model of age, sex, smoking, and the 10th percentile in the ADC histogram were better than those of their individual models and the combined model of age, sex, and smoking (all p < 0.05). Smoking and male sex, along with the median > 1.26 μm2/s, entropy > 4.03, and standard deviation (SD) > 0.4 of the ADC histogram, were significant predictors of TAO activity, with odds ratios of 2.741 and 6.806, 5.070, 2.652, and 2.197, respectively (all p < 0.05).

CONCLUSION

ADC histograms provide a new method for distinguishing active from inactive TAO, and the 10th percentile enhances the clinical diagnosis of active TAO. In addition to male sex and smoking, an ADC histogram median > 1.26 μm²/s, entropy > 4.03, or SD > 0.4 may also predict active TAO.

Teprotumumab for thyroid eye disease in patients with hypothyroid/euthyroid state: a multicenter case series

BACKGROUND

Teprotumumab, a novel IGF-1R antibody was recently shown to significantly reduce the signs of acute and chronic thyroid eye disease (TED) related to hyperthyroidism. Given the lower incidence of TED associated with hypothyroidism / euthyroidism, there is a paucity of data regarding the efficacy of teprotumumab in this group.

METHODS

In this multicenter study, consecutive patients who had been diagnosed with TED, presenting with either hypothyroidism or euthyroidism as their baseline thyroid dysfunction and treated with teprotumumab were included. All patients had measurements of proptosis, clinical activity scores (CAS), diplopia scores and four-point strabismus scores before and after therapy.

RESULTS

Twenty-six patients met the inclusion criteria. Mean age was 48 ± 14 years old and mean duration of TED prior to treatment was 31 ± 43 months. All patients received 8 infusions. Mean (SD) reduction in proptosis for study orbits was 2.7 mm (1.8) (p < 0.05) and 1.8 mm (2.0) for the fellow orbit (p < 0.05). In the study orbit, mean (SD) CAS was 2.3 (1.3) before therapy and 1.0 (1.0) following therapy (p < 0.05). At baseline, mean (SD) diplopia score was 1.2 (1.1) and 0.9 (1.1) following therapy (p < 0.05).

CONCLUSION

Teprotumumab reduces proptosis and inflammation in patients presenting with TED associated with hypothyroidism and euthyroidism. The results of this study highlight the potential for teprotumumab therapy in this subgroup and also provide a unique insight into the potential role of the IGF-1R in these patients.

Alpha-1 antagonist treatment for eyelid retraction in patients with thyroid eye disease-a prospective pilot study

BACKGROUND

Sympathetic overstimulation of Müller's muscle is a suggested mechanism underlying upper eyelid retraction in thyroid eye disease (TED). We examined the effect of tamsulosin, an alpha-1 antagonist, on eyelid retraction in patients with TED.

METHODS

A single-centre prospective study. Patients with TED and associated eyelid retraction were treated with oral 0.4 mg/day tamsulosin for 3 months. Upper eyelid margins-to-reflex distance (MRD1), vertical palpebral fissure height (PFH), subjective improvement, signs and symptoms of dry eye, and lubricants use were assessed at baseline and at each subsequent visit.

RESULTS

Eleven suitable patients (mean age 47.5 ± 9.68, 8 females) enrolled in the study. Three patients discontinued the drug due to mild adverse effects (dizziness, bradycardia, nausea, and gastrointestinal distress), which resolved immediately upon stopping treatment. The other eight patients tolerated the drug well and reported no side effects. Five patients experienced an objective improvement in eyelid position and subjective improvement in eye discomfort. The mean MRD1 decreased by -1.04 ± 0.81 mm (P = 0.015), and mean PFH decreased by -1.46 ± 1.33 mm (P = 0.039). Mean duration of tamsulosin treatment was 84.63 ± 71.9 days. Patients discontinued the drug due to no improvement in MRD1 (n = 3), referral for eyelid surgery with stable inactive TED (n = 2), treatment with intravenous methylprednisolone due to worsening active TED (n = 2), and patient choice after 5 months of treatment with spontaneous resolution of symptoms (n = 1).

CONCLUSIONS

Tamsulosin is a safe potential treatment for eyelid retraction in TED and can be used as a temporary alternative therapeutic approach for patients unsuitable for surgery.

[Lower eyelid retraction after inferior rectus recession in thyroid eye disease]

The involvement of extraocular muscles (EOMs) in the inflammatory process in thyroid eye disease (TED) often leads to fibrosis, persistent restrictive strabismus, and binocular diplopia. The inferior rectus muscle (IRM) is most commonly affected, resulting in vertical strabismus and hypotropia with significant limitation of upward gaze. Surgical management of restrictive strabismus in TED aims to increase the range of binocular eye movements, eliminate binocular diplopia, and correct the cosmetic defect associated with strabismus. The "gold standard" surgery involves weakening of the affected muscles, and is called muscle recession. In cases of severe fibrotic changes, maximal surgical intervention - so-called deep recession - is needed. Due to the anatomical characteristics of the capsulopalpebral fascia (CPF), the main component of the lower eyelid retractors, which originates from the inferior part of the IRM belly, deep IRM recession results in lower eyelid retraction. This significantly affects both the functional state of the lower eyelid (leading to lagophthalmos) and the symmetry of the palpebral fissures. Moderate lower eyelid retraction is typically managed with retractor dissection and lateral canthoplasty, whereas in severe cases various spacers are used. To minimize the number of surgical stages, techniques have been proposed for repositioning and dissecting the Lockwood ligament, specifically the CPF head, simultaneously with IRM recession. However, the effectiveness of these methods remains debatable, and the risk of intraoperative complications is high. Further research is needed to develop an optimal surgical approach for TED patients.

De novo thyroid eye disease following COVID vaccination several years after radioiodine therapy

The delayed onset of thyroid eye disease is well recognised but less commonly perceived in routine clinical practice and this case report serves as a reminder for a high index of suspicion in at-risk patients.

Autoimmune Thyroid Disease in Patients with Down Syndrome-Review

Down syndrome develops due to the presence of supernumerary chromosome 21. This diagnosis is made in approximately 1:800 live births. The tendency to develop autoimmune disorders like idiopathic arthritis, celiac disease, diabetes mellitus type 1, vitiligo and autoimmune thyroid disease is strongly expressed in patients with Down syndrome. Autoimmune thyroid diseases consisting of Hashimoto's thyroiditis and Graves' disease are specifically prevalent in patients with Down syndrome. The aim of our study is to collect available data connecting the pathogenesis and clinical course of autoimmune thyroid diseases in patients with Down syndrome of different ages and compare them to control groups. According to published data, the incidence ratio of Hashimoto's thyroiditis diagnosis in patients with Down syndrome is elevated compared to in age-matched controls without this chromosomal aberration, similarly to Graves' disease risk, which is also increased in a group of patients with Down syndrome. What is more, both Hashimoto's thyroiditis and Graves' disease are diagnosed at an earlier age than in the healthy population and are not correlated with gender or a family history of autoimmune diseases.

Patterns of Extraocular Muscle Enlargement in Graves' Orbitopathy and Acromegaly

Purpose: Extraocular muscle (EOM) enlargement occurs in both acromegaly and Graves' disease, but the degree and pattern of enlargement have not been directly compared in these patient groups. This study investigated whether acromegaly and Graves' orbitopathy (GO) are associated with different patterns of EOM enlargement at the time of diagnosis. Study Design: Retrospective cohort. Methods: All new patients with a diagnosis of acromegaly or GO who presented to St Joseph's Health Care in London, Ontario, between January 1, 2015, and July 1, 2020, and who underwent computed tomography (CT) scanning with adequate orbital imaging were considered for inclusion. We included age- and sex-matched control patients with pituitary macroadenomas without thyroid or growth hormone abnormalities. Orbital CT scans were analyzed by a single neuroradiologist, who measured the maximum diameter and cross-sectional area of each EOM. The relative likelihood of involvement of each rectus EOM was analyzed separately using an analysis of variance test. Results: We included 16 patients with GO, 17 with acromegaly, and 18 controls. Ages (mean ± standard deviation) of groups were 55.6 ± 18.0, 50.2 ± 15.7, and 49.3 ± 14.0 years. The mean maximum diameter of EOMs in GO, acromegaly, and controls was inferior rectus (IR) = 4.77 ± 1.53, 4.66 ± 0.61, and 3.68 ± 0.61 mm; medial rectus (MR) = 5.35 ± 2.23, 4.84 ± 0.81, and 3.65 ± 0.42 mm; superior rectus (SR) = 4.94 ± 1.84, 4.88 ± 0.91, and 3.68 ± 0.61 mm; and lateral rectus (LR) = 3.91 ± 1.59, 4.55 ± 0.60, and 3.20 ± 0.43 mm. The IR, MR, and SR muscles were significantly larger in the GO group compared with controls (IR, p = 0.020; SR, p = 0.004; MR, p < 0.001; and LR, p = 0.166), and all four EOMs were larger in acromegaly compared with controls (IR, p = 0.039; SR, p = 0.006; MR, p = 0.006; and LR, p = 0.001). There was no significant difference between the GO and acromegaly groups (IR, p = 0.959; SR, p = 0.987; MR, p = 0.408; and LR, p = 0.250). Conclusions: GO and acromegaly groups demonstrated the enlargement of the IR, MR, and SR muscles when compared with controls. The GO group did not show significantly larger EOM sizes compared with the acromegaly group. In the GO group, the IR, MR, and SR were similarly affected and did not follow previously described patterns of enlargement in GO.